Drug Trial Radar · NCT04148391
NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)
Last checked: Nov 19, 2026Latest source record: Oct 27, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
99
Actual
Start
Nov 14, 2019
Primary completion
Dec 30, 2022
Study completion Dec 30, 2022
Sponsor
- Lead sponsor
- AptinyxIndustry
- Sponsor type
- Industry
- Collaborators
- CogState Ltd.; Worldwide Clinical Trials
- First posted
- Nov 1, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Study to Evaluate NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Associated With Parkinson's Disease or Prodromal or Manifest Lewy Body Dementia
Conditions
- Mild Cognitive Impairment
- Mild Dementia
- Parkinson Disease
- Lewy Body Disease
Interventions
Placebo Oral CapsuleDrug
Matching placebo capsules.
NYX-458Drug
NYX-458 is a small molecule that modulates the N-methyl-D-aspartate receptor (NMDAR).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in physical examinationTime frame: Subjects will be followed up to 14 days post-dose
- Rates of adverse events and serious adverse eventsTime frame: Subjects will be followed up to 14 days post-dose
- Rates of early termination due to adverse eventsTime frame: Subjects will be followed up to 14 days post-dose
- Change from baseline in vital signs, clinical laboratory values, and electrocardiogram resultsTime frame: Subjects will be followed up to 14 days post-dose
- Change from baseline dissociative effects, psychosis, and hallucinatory symptoms as measured by the Neuropsychiatric Inventory (NPI-12)Time frame: Subjects will be followed up to 14 days post-dose
- Change from baseline in suicidal ideation and behavior as measured by the Sheehan Suicidality Tracking Scale (S-STS)Time frame: Subjects will be followed up to 14 days post-dose
- Change from baseline in motor complications as measured by the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part 4Time frame: Subjects will be followed up to 14 days post-dose
- Change in total score of the Sheehan Suicidality Tracking Scale (S-STS)Time frame: Subjects will be followed up to 14 days post-dose
Locations
26 sites in 1 country. Site status is shown where the registry gives one.
Aptinyx Clinical Site
Scottsdale, Arizona
Aptinyx Clinical Site
Fresno, California
Aptinyx Clinical Site
Simi Valley, California
Aptinyx Clinical Site
Boca Raton, Florida
Aptinyx Clinical Site
Bradenton, Florida
Aptinyx Clinical Site
Miami, Florida
Aptinyx Clinical Site
Miami, Florida
Aptinyx Clinical Site
Miami, Florida
Aptinyx Clinical Site
Miami, Florida
Aptinyx Clinical Site
Miami Lakes, Florida
Aptinyx Clinical Site
Orlando, Florida
Aptinyx Clinical Site
Port Charlotte, Florida
Aptinyx Clinical Site
Port Orange, Florida
Aptinyx Clinical Site
Sunrise, Florida
Aptinyx Clinical Site
Decatur, Georgia
Aptinyx Clinical Site
Farmington Hills, Michigan
Aptinyx Clinical Site
Golden Valley, Minnesota
Aptinyx Clinical Site
Toms River, New Jersey
Aptinyx Clinical Site
Poughkeepsie, New York
Aptinyx Clinical Site
Asheville, North Carolina
Aptinyx Clinical Site
Dayton, Ohio
Aptinyx Clinical Site
Tulsa, Oklahoma
Aptinyx Clinical Site
Round Rock, Texas
Aptinyx Clinical Site
Sugar Land, Texas
Aptinyx Clinical Site
Bellevue, Washington
Aptinyx Clinical Site
Spokane, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.